On August 25, 2025 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) reported that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons (Press release, Hutchison China MediTech, AUG 25, 2025, View Source [SID1234655457]). In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recovery. We thank Mr Cheng for his agreement to assume responsibility for overseeing the day-to-day operations and management of the Company during this interim period. The board has full confidence in Mr. Cheng’s capabilities to lead the Company. The Board is confident that all research, development and commercial initiatives will remain on track."

Dr Weiguo Su, Executive Director, said, "This has been a very difficult decision to make, but at this time my focus must be on my health. I am certain that the Board, Mr Cheng and everyone at HUTCHMED will ensure the continued execution of our strategy and that the scientific team will continue its work on the determined drug research and discovery pipeline as planned. I would like to thank everyone for their support and look forward to being able to return to work as soon as possible.

Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer, said, "Over the last 20 years under Dr Su’s leadership and the contribution of the entire team, HUTCHMED has built a portfolio of drugs and a strategy to successfully build new platforms and capabilities to deliver additional value. Together with our management team we shall endeavor to ensure on-track delivery. My best wishes to Dr Su for a speedy recovery."

On August 25, 2025 Eli Lilly and Company (NYSE:LLY) reported it will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D., Lilly chief medical officer will take part in a fireside chat at 9:15 a.m., Eastern time (Press release, Eli Lilly, AUG 25, 2025, View Source [SID1234655456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On August 25, 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reported it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen’s IMDELLTRA (tarlatamab-dlle) for up to $950 million to Royalty Pharma (Nasdaq: RPRX) (Press release, BeOne Medicines, AUG 25, 2025, View Source [SID1234655452]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, BeOne will receive an upfront payment of $885 million, with the option to sell remaining royalties within 12 months for up to $65 million. BeOne will share in a portion of the royalty on annual sales above $1.5 billion, and will maintain royalty and all other rights to other assets under the terms of the existing collaboration with Amgen, including xaluritamig, a first-in-class STEAP1 x CD3 XmAb currently being studied in patients with metastatic castration-resistant prostate cancer (mCRPC).

IMDELLTRA is a first-in-class immunotherapy that binds to both DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing cells. IMDELLTRA is approved in the United States for patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed on or after receiving platinum-based chemotherapy.

"Today’s announcement is testament to the value of our long-term collaboration with Amgen, the developer of IMDELLTRA, who recognized the potential of BeOne in advancing their oncology pipeline," said John V. Oyler, Co-Founder, Chairman and CEO of BeOne. "In the five years since entering into this collaboration, we have executed with purpose in advancing our mission to deliver multiple transformative medicines to more patients worldwide."
"This agreement meaningfully accelerates value realization for BeOne, while preserving continued participation in the long-term potential of IMDELLTRA," said Aaron Rosenberg, Chief Financial Officer, BeOne. "A strong balance sheet is a hallmark of the most successful companies in our industry, and this transaction provides increased operational and strategic flexibility as we continue to execute our business strategy for the long term."

About IMDELLTRA (tarlatamab-dlle)
IMDELLTRA is a first-in-class immunotherapy that binds to both DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing cells. This results in the formation of a cytolytic synapse with lysis of the cancer cell. DLL3 is a protein that is expressed on the surface of SCLC cells in the vast majority of patients with SCLC, but is minimally expressed on healthy cells, making it an exciting target.

Tarlatamab is being investigated in multiple studies including DeLLphi-303, a Phase 1b study evaluating tarlatamab in combination with standard of care therapies in first-line ES-SCLC; DeLLphi-304, a randomized Phase 3 trial comparing tarlatamab monotherapy with standard of care chemotherapy in second-line treatment of ES-SCLC; DeLLphi-306, a randomized placebo-controlled Phase 3 trial of tarlatamab following concurrent chemoradiotherapy in limited-stage SCLC; DeLLphi-308, a Phase 1b study evaluating subcutaneous tarlatamab in second line or later ES-SCLC; and DeLLphi-309, a Phase 2 study evaluating alternative intravenous dosing regimens with tarlatamab in second-line ES-SCLC.

On August 25, 2025 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8th – 10th, 2025 at the Lotte New York Palace Hotel in New York City (Press release, Anixa Biosciences, AUG 25, 2025, View Source [SID1234655451]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mike Catelani, President and CFO of Anixa, will deliver a presentation and will be available for one-on-one meetings during the conference.

Details of the presentation are as follows:

Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 8, 2025
Time: 4:30 PM ET
Location: Lotte New York Palace Hotel
Webcast: View Source

On August 25, 2025 Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, reported the completion of the first cohort in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001 (Press release, Akiram Therapeutics, AUG 25, 2025, https://akiramtherapeutics.se/clinical-phase-i-clinical-trial-with-akir001-progresses-to-next-step-following-completion-of-first-cohort/ [SID1234655450]). No safety signals have been observed, and the trial is now proceeding to the next stage as planned.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial is being conducted at Karolinska University Hospital, which also serves as the study sponsor. The aim is to evaluate safety, tolerability, and pharmacokinetics in patients with advanced, difficult-to-treat solid tumors.

Akiram’s drug candidate 177Lu-AKIR001 is a targeted radiopharmaceutical that combines an antibody directed against CD44v6—a cancer marker associated with several aggressive tumor types—with the therapeutic radioisotope lutetium-177. Through this mechanism, radiation can be delivered directly to tumor cells while minimizing impact on surrounding healthy tissue.

All patients planned for the first dose cohort have now been enrolled. No dose-limiting toxicities or other safety concerns have been observed.

"Completing the first cohort marks an important milestone for AKIR001. Our goal is to develop a treatment that reaches tumors with high selectivity and has a favorable safety profile. These initial clinical data support the next step in development," says Marika Nestor, CEO of Akiram Therapeutics.

"The completion of cohort 1 without unexpected side effects represents an important step forward. The results suggest that the drug is well tolerated at the doses tested so far, and we are pleased to proceed as planned," says Dr. Luigi De Petris, Principal Investigator at Karolinska University Hospital.

The trial is enrolling patients with anaplastic and iodine-refractory thyroid cancer, head and neck squamous cell carcinoma, gynecological squamous cell carcinoma, and non-small cell lung cancer. In the next phase, additional patients will be included to gather further data on dose response, safety, and early signs of efficacy.

The study is the result of a successful national collaboration between leading clinical and academic institutions in the field of precision oncology. The project is supported by the Swedish Cancer Society, the Sjöberg Foundation, the Erling-Persson Foundation, the Swedish Research Council, and Vinnova, Sweden’s Innovation Agency.

The trial is registered at ClinicalTrials.gov: NCT06639191.